Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)

Cell. 2023 Aug 17;186(17):3523-3523.e1. doi: 10.1016/j.cell.2023.07.031.ABSTRACTThe FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.PMID:37595560 | DOI:10.1016/j.cell.2023.07.031
Source: Herpes - Category: Infectious Diseases Authors: Source Type: research